Emergent Biosolutions (EBS) has shared an announcement.
Emergent BioSolutions Inc. has experienced a notable amendment to its contract with the U.S. Department of Health and Human Services, which now stipulates a reduced minimum purchase dose quantity for future option years and adjusts the price per dose accordingly. This change reflects a potential maximum contract value of $1.4 billion. Moreover, Emergent will be sharing its financial and operational achievements for the first quarter of 2024 in a forthcoming conference call, with related materials to be made available on their website.
For a thorough assessment of EBS stock, go to TipRanks’ Stock Analysis page.
